Latest Insider Transactions at Tarsus Pharmaceuticals, Inc. (TARS)
This section provides a real-time view of insider transactions for Tarsus Pharmaceuticals, Inc. (TARS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Tarsus Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Tarsus Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2021
|
Vivo Capital Ix, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
110,000
-3.49%
|
$3,080,000
$28.5 P/Share
|
|
Jun 21
2021
|
Vivo Capital Ix, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
91,620
-2.82%
|
$2,656,980
$29.7 P/Share
|
|
Jun 15
2021
|
Michael Ackermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,257
+0.34%
|
-
|
|
May 07
2021
|
Rtw Investments, LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
450,000
-18.27%
|
$13,050,000
$29.98 P/Share
|
|
Apr 14
2021
|
Vivo Capital Ix, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400
-0.01%
|
$12,000
$30.37 P/Share
|
|
Oct 20
2020
|
Bobak R. Azamian President/CEO and Board Chair |
BUY
Conversion of derivative security
|
Direct |
1,750
+50.0%
|
-
|
|
Oct 20
2020
|
Bobak R. Azamian President/CEO and Board Chair |
BUY
Conversion of derivative security
|
Indirect |
21,575
+1.72%
|
-
|
|
Oct 20
2020
|
Michael Ackermann Director |
BUY
Conversion of derivative security
|
Direct |
63,185
+2.49%
|
-
|
|
Oct 20
2020
|
Jason E. Tester Director |
BUY
Open market or private purchase
|
Indirect |
171,875
+8.99%
|
$2,750,000
$16.0 P/Share
|
|
Oct 20
2020
|
Jason E. Tester Director |
BUY
Conversion of derivative security
|
Indirect |
1,777,456
+25.89%
|
-
|
|
Oct 20
2020
|
William J Phd Link |
BUY
Conversion of derivative security
|
Indirect |
1,112,301
+50.0%
|
-
|
|
Oct 20
2020
|
Vivo Capital Ix, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
250,000
+7.15%
|
$4,000,000
$16.0 P/Share
|
|
Oct 20
2020
|
Vivo Capital Ix, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,995,035
+28.34%
|
-
|
|
Oct 20
2020
|
Horowitz Limited Partnership Viii > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
15,625
+19.1%
|
$250,000
$16.0 P/Share
|
|
Oct 20
2020
|
Horowitz Limited Partnership Viii > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
50,547
+31.38%
|
-
|
|
Oct 20
2020
|
Horowitz Limited Partnership Viii > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
168,750
+8.08%
|
$2,700,000
$16.0 P/Share
|
|
Oct 20
2020
|
Horowitz Limited Partnership Viii > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,752,183
+22.23%
|
-
|
|
Oct 20
2020
|
Frazier Life Sciences Ix, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
312,500
+14.02%
|
$5,000,000
$16.0 P/Share
|
|
Oct 20
2020
|
Frazier Life Sciences Ix, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,604,657
+30.89%
|
-
|